Simulations Plus Aktie
-
Deine Einschätzung
Simulations Plus Aktie
Was spricht für und gegen Simulations Plus in den nächsten Jahren?
Pro
Kontra
Rendite von Simulations Plus im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Simulations Plus | - | - | - | - | - | - | - |
MicroVision Inc | -0,09 % | -12,36 % | -16,42 % | -29,93 % | -45,50 % | -85,19 % | 46,58 % |
Fonar Corp. New | -1,91 % | -7,78 % | -22,61 % | 5,48 % | -12,99 % | 2,67 % | -9,83 % |
Allscripts Healthcare | 2,78 % | 0,00 % | 17,46 % | -33,33 % | -20,00 % | -42,64 % | -10,41 % |
Kommentare
News
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024.